Core Viewpoint - Acumen Pharmaceuticals is advancing its research on sabirnetug, a novel therapeutic targeting soluble amyloid beta oligomers for Alzheimer's disease, with new data to be presented at the upcoming AD/PD conference [1][2]. Group 1: Conference Presentations - Acumen will present one oral and two poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases from March 17-21, 2026, in Copenhagen [1]. - The oral presentation will focus on enhanced brain delivery of sabirnetug in a mouse model of Alzheimer's disease [3]. - The poster presentations will cover biomarker treatment responses and the development of novel antibodies targeting amyloid beta oligomers [4]. Group 2: Research and Development - The oral presentation on enhanced brain delivery is part of a collaboration with JCR Pharmaceuticals, aiming to improve drug delivery to the brain and develop more effective treatment options for Alzheimer's disease [4]. - Sabirnetug (ACU193) is a humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers, which are believed to be a significant factor in the neurodegenerative process of Alzheimer's disease [6]. - The ongoing Phase 2 clinical trial, ALTITUDE-AD, involves 542 participants and aims to evaluate the efficacy and safety of sabirnetug in slowing cognitive decline in early Alzheimer's disease [7]. Group 3: Company Overview - Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for Alzheimer's disease, leveraging its expertise in amyloid beta oligomers [8]. - The company is also exploring a subcutaneous formulation of sabirnetug using Halozyme's ENHANZE drug delivery technology [8]. - Acumen's scientific founders have pioneered research on amyloid beta oligomers, which are increasingly recognized as early triggers of Alzheimer's pathology [8].